Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 IMC-3G3 in previously treated unresectable or metastatic GIST
NL-OMON38170Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaratumab in gastrointestinal stromal tumor (GIST) (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Tumor response at 12 weeks and Imaging-based disease response assessments. Started Aug 2011; status: active, not recruiting.
02
Drugs
olaratumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON38170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38170.